title: Recurrent endometrial carcinoma: prognosis for patients with recurrence within 6 to 12 months is worse relative to those relapsing at 12 months or later.
abstract: OBJECTIVE
  We evaluated association of prognosis of endometrial carcinoma patients and treatment-free intervals (TFIs).
  
  
  METHODS
  We compared the effectiveness of second-line chemotherapy performed for patients with TFIs of 6-12 months and 12 or more months following a first-line chemotherapy based on taxane (paclitaxel) and carboplatin, with or without the anthracycline (TC).
  
  
  RESULTS
  Progression-free and overall survivals were significantly shorter in patients with TFIs of 6-12 months than those with TFIs of 12 or more months. Among the patients who received similar second-line chemotherapy, response rates of 15 patients with TFIs of 12 or more months and 7 patients with TFIs of 6-12 months were 67% and 43%, respectively. Progression-free survival was significantly worse in those with TFIs of 6-12 months (median, 7 months) than those with TFIs of 12 or more months (median, 12 months).
  
  
  CONCLUSIONS
  Our small retrospective analysis suggests that recurrent endometrial carcinomas with TFIs of 6-12 months can be regarded as being partially sensitive to TC-based chemotherapy.
authors.affiliation: Department of Obstetrics and Gynecology, Osaka Rosai Hospital, Japan.
authors.forename: Takahito
authors.initials: T
authors.lastname: Miyake
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ueda
authors.forename: Tomomi
authors.initials: T
authors.lastname: Egawa-Takata
authors.forename: Shinya
authors.initials: S
authors.lastname: Matsuzaki
authors.forename: Takuhei
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Yukari
authors.initials: Y
authors.lastname: Miyoshi
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Kimura
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Yoshino
authors.forename: Masami
authors.initials: M
authors.lastname: Fujita
authors.forename: Masato
authors.initials: M
authors.lastname: Yamasaki
authors.forename: Takayuki
authors.initials: T
authors.lastname: Enomoto
authors.forename: Tadashi
authors.initials: T
authors.lastname: Kimura
mesh_terms: D016889:Endometrial Neoplasms / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000453:epidemiology*; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors